Skip to main content
. 2016 Mar 1;7(4):544–554. doi: 10.1111/jdi.12471

Figure 2.

Figure 2

Distribution of changes in bodyweight from baseline to the end of treatment in the placebo (n = 321) and ipragliflozin (n = 508) groups. The median change in bodyweight was −0.5 and −2.2 kg in the placebo and ipragliflozin groups, respectively. A reduction in bodyweight of ≥5% from the baseline value was observed in 5.0 and 23.2% of patients in the placebo and ipragliflozin groups, respectively (P < 0.001).